Loading...
P16.01 Surgery for recurrent high grade glioma after treatment with bevacizumab
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which is FDA-approved for the treatment of recurrent glioblastoma. There is some evidence for bevacizumab inducing a treatment-resistant tumor phenotype, by selecting for more infiltrative cells which can subsist witho...
Saved in:
| Published in: | Neuro Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Oxford University Press
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464244/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.417 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|